The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Genomic spectra of biliary tract cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200015 · Cited by 1,217
Self-citationLiver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 969
Self-citationBrindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 841
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
Zhang, M., Yang, H., Wan, L., Wang, Z., Wang, H., Ge, C., Liu, Y., Hao, Y., Zhang, D., Shi, G., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.039 · Cited by 605
Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., Kemeny, N. E., O'Reilly, E. M., El-Dika, I., Jarnagin, W. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0078 · Cited by 582
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma
Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., Forgues, M., Pomyen, Y., Bhudhisawasdi, V., Lertprasertsuke, N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.009 · Cited by 434
Self-citationJavle, M., Roychowdhury, S., Kelley, R. K., Sadeghi, S., Macarulla, T., Weiss, K. H., Waldschmidt, D.-T., Goyal, L., Borbath, I., El-Khoueiry, A., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00196-5 · Cited by 428
Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update
Sharma, A., Sharma, K. L., Gupta, A., Yadav, A., & Kumar, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i22.3978 · Cited by 424
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 412
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 405
Roa, J. C., García, P., Kapoor, V. K., Maithel, S. K., Javle, M., & Koshiol, J. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00398-y · Cited by 401
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 390
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 382
Sunami, K., Ichikawa, H., Kubo, T., Kato, M., Fujiwara, Y., Shimomura, A., Koyama, T., Kakishima, H., Kitami, M., Matsushita, H., et al. (2019) · Cancer Science · doi:10.1111/cas.13969 · Cited by 378
Self-citationGoyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0182 · Cited by 376
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P., Kim, J., Hatanaka, Y., Maejima, K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.009 · Cited by 373
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., & Carpino, G. (2019) · Liver International · doi:10.1111/liv.14093 · Cited by 350
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochin, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 344
Job, S., Rapoud, D., Dos Santos, A., Gonzalez, P., Desterke, C., Pascal, G., Elarouci, N., Ayadi, M., Adam, R., Azoulay, D., et al. (2020) · Hepatology · doi:10.1002/hep.31092 · Cited by 322
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica, A. E., Gores, G. J., Groopman, J. D., Selaru, F. M., Strazzabosco, M., Wei Wang, X., & Zhu, A. X. (2019) · Hepatology · doi:10.1002/hep.30289 · Cited by 315
Oh, D.-Y., Lee, K.-H., Lee, D.-W., Yoon, J., Kim, T.-Y., Bang, J.-H., Nam, A.-R., Oh, K.-S., Kim, J.-M., Lee, Y., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00043-7 · Cited by 311
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres-Martin, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 301
Xue, R., Chen, L., Zhang, C., Fujita, M., Li, R., Yan, S.-M., Ong, C. K., Liao, X., Gao, Q., Sasagawa, S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.007 · Cited by 296
Dai, Z., Liu, H., Liao, J., Huang, C., Ren, X., Zhu, W., Zhu, S., Peng, B., Li, S., Lai, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.003 · Cited by 294
Harding, J. J., Fan, J., Oh, D.-Y., Choi, H. J., Kim, J. W., Chang, H.-M., Bao, L., Sun, H.-C., Macarulla, T., Xie, F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00242-5 · Cited by 291
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 259
Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02038-4 · Cited by 258
Self-citationMetabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids
Artegiani, B., van Voorthuijsen, L., Lindeboom, R. G. H., Seinstra, D., Heo, I., Tapia, P., López-Iglesias, C., Postrach, D., Dayton, T., Oka, R., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.017 · Cited by 218
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Portrait of a cancer: mutational signature analyses for cancer diagnostics
Van Hoeck, A., Tjoonk, N. H., van Boxtel, R., & Cuppen, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5677-2 · Cited by 107
Goeppert, B., Roessler, S., Renner, M., Singer, S., Mehrabi, A., Vogel, M. N., Pathil, A., Czink, E., Köhler, B., Springfeld, C., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0199-2 · Cited by 108
Wu, Q., Zhen, Y., Shi, L., Vu, P., Greninger, P., Adil, R., Merritt, J., Egan, R., Wu, M.-J., Yin, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1168 · Cited by 104
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Khosla, D., Misra, S., Chu, P. L., Guan, P., Nada, R., Gupta, R., Kaewnarin, K., Ko, T. K., Heng, H. L., Srinivasalu, V. K., et al. (2024) · Cancers · doi:10.3390/cancers16040801 · Cited by 44
“In patients with CCA, around 2–3% had microsatellite instability (MSI-H) tumors, and 4–6% with a high tumor mutation burden (TMB-H) were noted [158,159].”
BackgroundMcNamara, M. G., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., Ryder, W. D., Barber, S., Gnanaranjan, C., Ghazaly, E., et al. (2021) · The Oncologist · doi:10.1002/onco.13598 · Cited by 25
Metadata
- Authors
- Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., Hiraoka, N., Ojima, H., Shimada, K., Okusaka, T., Kosuge, T., Miyagawa, S., & Shibata, T.
- Venue
- Nature Genetics
- Published
- 2015-08-10
- Volume
- 47
- Issue
- 9
- Pages
- 1003-1010
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1903979702
- Cited by
- 1,284
- References
- 44
- FWCI
- 57.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.